Bronchodilator Drugs - Portugal | Statista Market Forecast

In Portugal, the revenue in the market of Bronchodilator Drugs market is expected to reach US$67.81m in 2024.
It is projected to show an annual growth rate of 3.94% from 2024 to 2029, resulting in a market volume of US$82.26m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue of US$17.34bn in 2024.
Portugal has seen a surge in the demand for bronchodilator drugs due to the high prevalence of respiratory diseases in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are widely used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Portugal, the market for bronchodilator drugs has been growing steadily in recent years.

Customer preferences: Patients suffering from respiratory diseases in Portugal prefer bronchodilator drugs as they provide quick relief from symptoms such as shortness of breath, wheezing, and coughing. Moreover, these drugs are available in various forms such as inhalers, tablets, and syrups, making them convenient for patients to use.

Trends in the market: The bronchodilator drugs market in Portugal has been witnessing a shift towards combination therapies. Combination therapies involve the use of two or more drugs to treat respiratory diseases. This trend is driven by the need for more effective treatment options and the desire to simplify treatment regimens for patients. Moreover, the market is also witnessing the introduction of new bronchodilator drugs with improved efficacy and safety profiles.

Local special circumstances: The prevalence of respiratory diseases in Portugal is higher than the European average. According to the European Lung Foundation, Portugal has one of the highest asthma prevalence rates in Europe. This high prevalence of respiratory diseases has led to a significant demand for bronchodilator drugs in the country.

Underlying macroeconomic factors: The Portuguese healthcare system has been undergoing reforms in recent years, aimed at improving the efficiency and effectiveness of healthcare services. These reforms have led to an increase in the availability of healthcare services and the adoption of new technologies. Moreover, the government has been investing in the development of the pharmaceutical industry, which has led to the growth of the bronchodilator drugs market in the country.In conclusion, the bronchodilator drugs market in Portugal is driven by the high prevalence of respiratory diseases in the country and the availability of new and more effective treatment options. The market is expected to continue to grow in the coming years, driven by the increasing demand for combination therapies and the government's continued investment in the healthcare and pharmaceutical sectors.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.